Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates

Prostaglandins and Other Lipid Mediators

Volumn 92, Issue 1-4, 2010, Pages 33-43

  Hicks, Alexandra ^a   Goodnow Jr , Robert ^a   Cavallo, Gary ^a   Tannu, Shahid A ^a   Ventre, Jessica D ^a   Lavelle, Danielle ^a   Lora, Jose M ^a   Satjawatcharaphong, John ^a   Brovarney, Martin ^a   Dabbagh, Karim ^a   Tare, Nadine S ^a   Oh, Hyesun ^a   Lamb, Martin ^a   Sidduri, Achyutharao ^a   Dominique, Romyr ^a   Qiao, Qi ^a   Lou, Jian Ping ^a   Gillespie, Paul ^a   Fotouhi, Nader ^a   Kowalczyk, Agnieszka ^a   Kurylko, Grazyna ^a   Hamid, Rachid ^a   Wright, Matthew B ^a   Pamidimukkala, Anjula ^a   Egan, Thomas ^a   Gubler, Ueli ^a   Hoffman, Ann F ^a   Wei, Xin ^a   Li, Ying L ^a   O'Neil, John ^a   Marcano, Ruben ^a   Pozzani, Karen ^a   Molinaro, Tina ^a   Santiago, Jennifer ^a   Singer, Laura ^a   Hargaden, Maureen ^a   Moore, David ^a   Catala, A Robert ^a   Chao, Lisa C F ^a   Benson, Janet ^b   March, Thomas ^b   Venkat, Radhika ^a   Mancebo, Helena ^a   Renzetti, Louis M ^a   more..

^a Department of RNA Therapeutics Roche ^*  (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

BLT receptors; Guinea pig; LTB4; Lung inflammation; Mouse; Non human primate; Rat

Indexed keywords

4 [3 [6 (3 BENZO[1,3]DIOXOL 5 YL 5 THIOPHEN 3 YLPHENOXY) HEXYL] 2 (2 CARBOXYETHYL) PHENOXY] BUTYRIC ACID; ALLERGEN; BUDESONIDE; CIGARETTE SMOKE; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; RO 5101576; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOPY; CALCIUM MOBILIZATION; CELL STRAIN HL 60; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; LOEFFLER PNEUMONIA; MACACA; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NEUTROPHILIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMONIA; RAT; TOXICITY TESTING;

ANIMALS; BENZODIOXOLES; DOGS; DRUG TOXICITY; FEMALE; GUINEA PIGS; HL-60 CELLS; HUMANS; HYPERSENSITIVITY; LIPOPOLYSACCHARIDES; LUNG; MALE; MICE; OZONE; PHENYLPROPIONATES; PNEUMONIA; PRIMATES; RATS; RECEPTORS, LEUKOTRIENE B4; SMOKING; TOXICITY TESTS;

EID: 77952104701     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2010.02.003     Document Type: Article

References (40)

1. Barnes P.J. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 119 5 (2007) 1055-1062
2. Cowburn A.S., Condliffe A.M., Farahi N., Summers C., and Chilvers E.R. Advances in neutrophil biology: clinical implications. Chest 134 (2008) 606-612
3. O'Donnell R.A., Peebles C., Ward J.A., et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 59 (2004) 837-842
4. Macdowell A.L., and Peters S.P. Neutrophils in asthma. Curr Allergy Asthma Rep 7 (2007) 464-468
5. Tager A.M., and Luster A.D. BLT1 and BLT2: the leukotriene B4 receptors. Prostaglandins Leukotrienes Essential Fatty Acids 69 (2003) 123-134
6. Kim N.D., and Luster A.D. Regulation of immune cells by eicosanoids receptors. Scientific World J 7 (2007) 1307-1328
7. Hicks A., Monkarsh S.P., Hoffman A.F., and Goodnow Jr. R. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Exp Opin Invest Drugs 16 12 (2007) 1909-1920
8. Kamohara M., Takasaki J., Matsumoto M., et al. Molecular cloning and characterization of another leukotriene B4 receptor. J Biol Chem 275 (2000) 27000-27004
9. Profita M., Sala A., Riccobono L., et al. 15(S)-HETE modulates LTB(4) production and neutrophil chemotaxis in chronic bronchitis. Am J Physiol Cell Physiol 279 4 (2000) C1249-C1258
10. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., and Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384 (1996) 39-43
11. Masclans J.R., Sabater J., Sacanell J., et al. Possible prognostic value of leukotriene B(4) in acute respiratory distress syndrome. Respir Care 52 12 (2007) 1695-1700
12. Stephenson A.H., Lonigro A.J., Hyers T.M., Webster R.O., and Fowler A.A. Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS. Am Rev Respir Dis 138 3 (1988) 714-719
13. VanderMeer T.J., Menconi M.J., O'Sullivan B.P., et al. Acute lung injury in endotoxemic pigs: role of leukotriene B4. J Appl Physiol 78 3 (1995) 1121-1131
14. Rittirsch D., Flierl M.A., Day D.E., et al. Acute lung injury induced by lipopolysaccharide is independent of complement activation. J Immunol 180 11 (2008) 7664-7672
15. Izumo T., Kondo M., and Nagai A. Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis. Eur Respir J 34 6 (2009) 1444-1451
16. Corhay J.L., Henket M., Nguyen D., Duysinx B., Sele J., and Louis R. LTB4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD. Chest 136 4 (2009) 1047-1054
17. Lee E., Lindo T., Jackson N., et al. Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am J Respir Crit Care Med 160 (1999) 2079-2085
18. Grönke L., Beeh K.M., Cameron R., et al. Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 21 2 (2008) 409-417
19. Evans D.J., Barnes P.J., Spaethe S.M., van Alstyne E.L., Mitchell M.I., and O'Connor B.J. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 51 (1996) 1178-1184
20. Dominique R., Fotouhi N., Gillespie P., et al. Phenoxybutyric acid derivatives as leukotriene B4 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. PCT Int Appl 113 (2009) WO 2009024492 A1
21. Silbaugh S.A., Stengel P.W., Cockerham S.L., et al. Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY293111: in vivo pulmonary studies. Naunyn Schmiedebergs Arch Pharmacol 361 4 (2000) 397-404
22. Anderson G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 372 (2008) 1107-1119
23. Chabannes B., Hosni R., Molière P., et al. Leukotriene B4 level in neutrophils from allergic and healthy subjects stimulated by low concentration of calcium ionophore A23187. Effect of exogenous arachidonic acid and possible endogenous source. Biochim Biophys Acta 1093 1 (1991) 47-54
24. Ruzicka T., and Ring J. Enhanced releasability of prostaglandin E2 and leukotrienes B4 and C4 from leukocytes of patients with atopic eczema. Acta Derm Venereol 67 6 (1987) 469-475
25. Turner C.R., Breslow R., Conklyn M.J., et al. In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma. J Clin Invest 97 2 (1986) 381-387
26. Ciencewicki J., Trivedi S., and Kleeberger S.R. Oxidants and the pathogenesis of lung diseases. J Allergy Clin Immunol 122 3 (2008) 456-468
27. 3-induced change in bronchial reactivity to methacholine and airway inflammation in humans. J Appl Physiol 60 (1986) 1321-1326
28. Stevens W.H., Vanderheyden C., Wattie J., Lane C.G., Smith W., and O'Byrne P.M. Effect of a leukotriene B4 receptor antagonist SC-53228 on ozone-induced airway hyperresponsiveness and inflammation in dogs. Am J Crit Care Med 152 (1995) 1443-1448
29. Alfaro M.F., Walby W.F., Adams W.C., and Schelegle E.S. Breath condensate levels of 8-isoprostane and leukotriene B4 after ozone inhalation are greater in sensitive versus nonsensitive subjects. Exp Lung Res 33 3-4 (2007) 115-133
30. Bosma K.J., and Lewis J.F. Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs 12 3 (2007) 461-477
31. Boie Y., Stocco R., Sawyer N., et al. Characterization of the cloned guinea pig leukotriene B4 receptor: comparison to its human orthologue. Eur J Pharmacol 380 2-3 (1999) 203-213
32. Sharma R., Kaundal R.K., and Sharma S.S. Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs. Pulm Pharmacol Ther 22 3 (2009) 183-189
33. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 4 (2005) 258-266
34. Sato E., Koyama S., Takamizawa A., et al. Smoke extract stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activities. Am J Physiol 277 6 Pt 1 (1999) L1149-57
35. Masubuchi T., Koyama S., Sato E., et al. Smoke extract stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Pathol 153 6 (1998) 1903-1912
36. Thornton Jr. W.H., Adelstein E.H., and Edes T.E. Leukotriene B4 is measurable in serum of smokers and nonsmokers. Clin Chem 35 3 (1989) 459-460
37. Dhami R., Gilks B., Xie C., Zay K., Wright J.L., and Churg A. Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-antitrypsin. Am J Respir Cell Mol Biol 22 2 (2000) 244-252
38. Fox J.C., and Fitzgerald M.F. Models of chronic obstructive pulmonary disease: a review of current status. Drug Disc Today: Dis Mod 1 3 (2004) 319-328
39. Rogers D.F., and Jeffery P.K. Inhibition of cigarette smoke-induced airway secretory cell hyperplasia by indomethacin, dexamethasone, prednisolone, or hydrocortisone in the rat. Exp Lung Res 10 3 (1986) 285-298
40. Marwick J.A., Kirkham P.A., Stevenson C.S., et al. Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol 31 6 (2004) 633-642